GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » Shares Buyback Ratio %

CTXR (Citius Pharmaceuticals) Shares Buyback Ratio % : -13.77 (As of Dec. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Citius Pharmaceuticals Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Citius Pharmaceuticals's current shares buyback ratio was -13.77%.

Citius Pharmaceuticals Shares Buyback Ratio % Historical Data

The historical data trend for Citius Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Shares Buyback Ratio % Chart

Citius Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.60 -92.11 -162.66 -0.16 -8.65

Citius Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.54 - -0.07 -0.08 -13.60

Citius Pharmaceuticals Shares Buyback Ratio % Calculation

Citius Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2022 ) - Shares Outstanding (EOP) (A: Sep. 2023 )) / Shares Outstanding (EOP) (A: Sep. 2022 )
=(5.84844 - 6.35431) / 5.84844
=-8.65%

Citius Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Jun. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2024 )) / Shares Outstanding (EOP) (A: Mar. 2024 )
=(6.36379 - 7.22902) / 6.36379
=-13.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Pharmaceuticals Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » Shares Buyback Ratio %
Comparable Companies
PBYI TALS XFOR TNYA CARM ANNX TRVI BTAI XBIT INMB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
47N0:Germany
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Website
https://www.citiuspharma.com
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Executives
Myron Z Holubiak director, officer: Vice Chairman C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Leonard L Mazur director, 10 percent owner, officer: Chief Executive Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Suren G Dutia director C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Carol Webb director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
Eugene Myron Holuka director 11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016
Jaime Bartushak officer: Chief Financial Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Myron Czuczman officer: Chief Medical Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Howard Safir director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
William Kane director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016